{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":25,"n_cols":5,"rows_kept":25,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[12,2,12,3],[13,2,13,3],[17,2,17,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910555016503321"]
[null,null,"Autore",null,"Walsh Christopher"]
[null,null,"Titolo",null,"Antibiotics : challenges, mechanisms, opportunities / / by Christopher Walsh and Timothy Wencewicz"]
[null,null,"Pubbl/distr/stampa",null,"Washington, District of Columbia : , : ASM Press, , 2016"]
[{"$nulls":4},"©2016"]
[null,null,"ISBN",null,"1-68367-331-X"]
[{"$nulls":4},"1-55581-931-1"]
[null,null,"Descrizione fisica",null,"1 online resource (490 p.)"]
[null,null,"Disciplina",null,"615.329"]
[null,null,"Soggetti",null,"Antibiotics"]
[{"$nulls":4},"Drug resistance in microorganisms"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Contents; Preface; Section I: Challenges for Antibiotics; 1 Antibiotics: Initial Concepts and Considerations; Waves of Resistant Bacterial Infections; Differential Susceptibility to Antibiotics; Empiric Therapy and Broad-spectrum Antibiotics; Antibiotic Flow Chart; Recent Approvals and the Current Antibiotic Pipeline; Recognition of Pressing Need for New Antibiotics: \"The End is Near\" Scenarios; Approach and Organization of This Volume; 2 Major Classes of Antibiotics and Their Modes of Action; Antibiotics Versus Antimicrobials: Antibacterial Versus Antifungal Versus Antiprotozoal Agents"]
[{"$nulls":4},"What Bacteria to TargetHow to Test for Antibiotic Activity; How to Find Antibiotics; A Golden Age of Antibiotic Medicinal Chemistry; What is the Capacity for Microbes to Make Antibiotics?; Target Classes Identified from the Major Antibiotic Groups; A Common Pathway for Bactericidal Antibiotics?; Section II: Mechanisms: Antibiotic Action by Bacterial Target Class; 3 Assembly of the Peptidoglycan Layer of Bacterial Cell Walls; Introduction; Nature of the PG Layer of the Cell Envelope; Biosynthesis and Insertion of PG Monomer Units"]
[{"$nulls":4},"PG Assembly: Phase 1 in the Cytoplasm-Generation of UDP-Muramyl PentapeptidePG Assembly: Phase 2 at the Inner Face of the Cytoplasmic Membrane-the C55 Bactoprenol Lipid Carrier; PG Assembly: Phase III-Chain Extension and Cross-Linking at the Outer Face of the Cytoplasmic Membrane; Summary; 4 Antibiotics That Block "]
[{"$nulls":4},"Peptidoglycan Assembly and Integrity; Introduction; PG Transpeptidase Inhibition: β-Lactam Antibiotics; Four Subclasses of Antibiotics: Penams, Cephems, Carbapenems, and Monobactams; Mechanisms of Action of Lactam Antibiotics: Acylation of Transpeptidases; The Families of PBPs"]
[{"$nulls":4},"Acyl Enzyme Lifetimes Are CrucialPBP Inventories; Many Side Chain Variants in Semisynthetic β-Lactam Antibiotics; The Future for β-Lactam Antibiotics?; Moenomycin: Inhibition of PG Transglycosylases; Antibiotics That Act as Substrate Binders and Sequestrants in the Bactoprenol Metabolic Cycle; MraY and Peptidyl Nucleoside Antibiotics; How Do Bacteria Respond to Categories of Antibiotics That Target the Cell Wall?; 5 Antibiotics That Disrupt Membrane Integrity; Introduction; Antimicrobial Peptides and Defensins; Lantibiotic Peptides"]
[{"$nulls":4},"Calprotectin, an Antimicrobial Protein That Complexes Mn(II) and Fe(II)Bacterial Lipopeptides; Surfactin; Daptomycin Disrupts Bacterial Membrane Integrity; Polymyxin: an Old Antibiotic Revisited; Dual Mechanisms for SecondGeneration Lipoglycopeptide Antibiotics; 6 Antibiotics That Block Protein Synthesis; Overview of Bacterial Protein Synthesis; Antibiotics That Target Aminoacyl-tRNA Synthetases; Antibiotics That Target the Bacterial Ribosome; EF-Tu: an Aminoacyl-tRNA Chaperone as Antibiotic Target; 7 Antibiotics That Target DNA and RNA Information Transfer"]
[{"$nulls":4},"Antibiotics Directed against Type II Topoisomerases"]
[null,null,null,"Sommario/riassunto","Antibiotics: Challenges, Mechanisms, Opportunities focuses on antibiotics as small organic molecules, from both natural and synthetic sources. Understanding the chemical scaffold and functional group structures of the major classes of clinically useful antibiotics is critical to understanding how antibiotics interact selectively with bacterial targets."]